Virtual Town Hall
Wednesday, July 29nd 2020 @ 12:00pm EST
You are cordially invited to attend Helix BioPharma presenting at the AlphaBronze Virtual Town Hall, taking place on Wednesday, July 29nd at 12:00pm EST
Helix BioPharma – Town Hall Agenda
CEO Presentation – 10 to 15 minutes
Follow-up Q&A – 10 to 15 minutes
https://zoom.us/webinar/register/WN_0tdX0OQrTuS_gJCk53zVTQ
After registering, you will receive a confirmation email containing information about joining the webinar.
For more information on Helix BioPharma: https://www.helixbiopharma.com
Speaker – CEO Dr. Heman Chao
Dr. Chao will give an overview of the Company, its Lung Cancer and Pancreatic Cancer Clinical programs and upcoming milestones. Dr. Chao will respond to Investors questions thereafter.
Helix BioPharma Corp. (TSX: HBP) is a clinical-stage biotech, focused on immuno-oncology. The biotech is specializing in the field of cancer therapy and actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies, DOS47. Its patented oncology platform technology – DOS47 – offers a new and revolutionary approach to the debilitation and destruction of cancer cells by modulating the tumor microenvironment.
Founded in 1995, Helix BioPharma is based in Toronto. Helix Clinical Trials and programs’ focus are on Lung and Pancreatic cancer. In December 2019, it started patient’s enrollment for its L-DOS47 Phase lb/ll Pancreatic Cancer Clinical Study. Pancreatic cancer is an important cause of cancer death in the US – with few treatment options.